Drugs / Depo-medroxyprogesterone acetate
Depo-medroxyprogesterone acetate
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01421368 | Mar 2012 → Mar 2014 | — | CONRAD | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00161447 | May 2004 → Apr 2006 | — | University of Washington | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06816901 | Mar → Jul 2025 | lactation disease | University of California, San Diego | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05044962 | Nov 2021 → Mar 2027 expected | HIV infectious disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT02146248 | May 2014 → Jan 2015 | fallopian tube disorder | Jeffrey Jensen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | depomedroxyprogesterone acetate | “Depo-medroxyprogesterone acetate (DepoProvera®)” NCT02146248 ↗4“depomedroxyprogesterone acetate (DMPA)” PMID 16940442 ↗ Aug 2006 |
| Known as | DepoProvera | “Depo-medroxyprogesterone acetate (DepoProvera®)” NCT02146248 ↗ |
| Known as | DMPA | “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT05044962 ↗2“Depo-medroxyprogesterone acetate (DMPA)” NCT01421368 ↗ “depomedroxyprogesterone acetate (DMPA)” PMID 16940442 ↗ Aug 2006 |
| Known as | MPA | “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT05044962 ↗ |
| Route | Intramuscular | “depomedroxyprogesterone acetate (300 mg intramuscularly every 12 weeks)” PMID 17494097 ↗ May 2007 |